- Home
- BBIO vs SNN Comparison
BBIO vs SNN Comparison
Compare BBIO & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BBIO | SNN |
|---|---|---|
| Founded | 2015 | 1856 |
| Country | United States | United Kingdom |
| Employees | N/A | 16988 |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7B | 14.3B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | BBIO | SNN |
|---|---|---|
| Price | $67.48 | $30.60 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 25 | 2 |
| Target Price | ★ $86.33 | $36.25 |
| AVG Volume (30 Days) | ★ 2.8M | 1.1M |
| Earning Date | 05-12-2026 | 03-16-2026 |
| Dividend Yield | N/A | ★ 2.48% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $502,076,000.00 | N/A |
| Revenue This Year | $89.45 | $8.58 |
| Revenue Next Year | $73.78 | $5.60 |
| P/E Ratio | ★ N/A | $64.97 |
| Revenue Growth | ★ 126.26 | N/A |
| 52 Week Low | $38.57 | $28.40 |
| 52 Week High | $84.94 | $38.79 |
Technical Indicators
Market Signals| Indicator | BBIO | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 46.98 | 50.56 |
| Support Level | $62.37 | $29.08 |
| Resistance Level | $69.85 | $31.15 |
| Average True Range (ATR) | 2.77 | 0.51 |
| MACD | 0.10 | 0.14 |
| Stochastic Oscillator | 46.43 | 73.89 |
Price Performance
Historical ComparisonAbout BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.